BioRestorative Therapies Inc (BRTX)vsNovartis AG ADR (NVS)

BRTX

BioRestorative Therapies Inc

NASDAQ

$0.41

-2.24%

HEALTHCARE · Cap: $10.56M

NVS

Novartis AG ADR

NYSE

$148.38

-0.96%

HEALTHCARE · Cap: $273.77B

⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 15729119% more annual revenue ($56.58B vs $359,700). NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 49/100 (D+).

BRTX

Avoid

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 5.0Quality: 6.0

Piotroski: 3/9Altman Z: -69.86

NVS

Hold

out of 100

Grade: D+

Growth: 3.3Profit: 9.0Value: 3.3Quality: 4.5

Piotroski: 4/9Altman Z: 1.96

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BRTX.

NVSSignificantly Overvalued (-62.1%)

Margin of Safety

-62.1%

Fair Value

$91.39

Current Price

$148.38

$56.99 premium

UndervaluedFair: $91.39Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BRTX1 strengths · Avg: 10.0/10

Debt/EquityHealth

0.0110/10

Conservative balance sheet, low leverage

NVS5 strengths · Avg: 9.4/10

Market CapQuality

$273.77B10/10

Mega-cap, among the largest globally

Return on EquityProfitability

35.1%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability

30.5%10/10

Strong operational efficiency at 30.5%

Profit MarginProfitability

23.9%9/10

Keeps 24 of every $100 in revenue as profit

Free Cash FlowQuality

$2.87B8/10

Generating 2.9B in free cash flow

Areas to Watch

BRTX4 concerns · Avg: 3.5/10

Price/BookValuation

10.1x4/10

Trading at 10.1x book value

EPS GrowthGrowth

0.0%4/10

0.0% earnings growth

Market CapQuality

$10.56M3/10

Smaller company, higher risk/reward

Profit MarginProfitability

0.0%3/10

0.0% margin — thin

NVS4 concerns · Avg: 2.8/10

Altman Z-ScoreHealth

1.964/10

Grey zone — moderate risk

Debt/EquityHealth

1.223/10

Elevated debt levels

PEG RatioValuation

3.932/10

Expensive relative to growth rate

Revenue GrowthGrowth

-0.7%2/10

Revenue declined 0.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : BRTX

The strongest argument for BRTX centers on Debt/Equity.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.

Bear Case : BRTX

The primary concerns for BRTX are Price/Book, EPS Growth, Market Cap.

Bear Case : NVS

The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.

Key Dynamics to Monitor

BRTX profiles as a value stock while NVS is a declining play — different risk/reward profiles.

NVS carries more volatility with a beta of 0.49 — expect wider price swings.

NVS is growing revenue faster at -0.7% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

NVS scores higher overall (49/100 vs 18/100), backed by strong 23.9% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

BioRestorative Therapies Inc

HEALTHCARE · BIOTECHNOLOGY · USA

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols that primarily involve adult stem cells. The company is headquartered in Melville, New York.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Compare with Other BIOTECHNOLOGY Stocks

BRTX vs VRTX BRTX vs REGN BRTX vs ARGX BRTX vs ALNY BRTX vs RVMD NVS vs VRTX NVS vs REGN NVS vs ARGX NVS vs ALNY NVS vs RVMD

Want to dig deeper into these stocks?

Full BRTX Analysis →Full NVS Analysis →